2-甲基噻唑-5-基)甲醇 | 56012-38-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-甲基噻唑-5-基)甲醇
• 中文别名: (2-甲基-1,3-噻唑-5-基)甲醇
• 英文名称: (2-methylthiazol-5-yl)methanol
• 英文别名: 2-methyl-5-(hydroxymethyl)thiazole；5-(hydroxymethyl)-2-methylthiazole；(2-Methyl-1,3-thiazol-5-yl)methanol
• CAS: 56012-38-5
• 化学式: C₅H₇NOS
• mdl: MFCD12912988
• 分子量: 129.183
• InChiKey: UGNOVENEUBRGNI-UHFFFAOYSA-N

物化性质

• 沸点：
  117.5 °C(Press: 3 Torr)
• 密度：
  1.263±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C，应密封保存，并保持干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (2-Methyl-1,3-thiazol-5-yl)methanol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (2-Methyl-1,3-thiazol-5-yl)methanol
CAS number: 56012-38-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H7NOS
Molecular weight: 129.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基噻唑-5-基)甲醇 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 17.0h， 以2.8 g的产率得到5-(chloromethyl)-2-methylthiazole
  参考文献：
  名称：

  [EN] BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS AMIDES HÉTÉROAROMATIQUES BICYCLIQUES ET LEURS UTILISATIONS

  摘要：

  本发明涉及一些在治疗神经系统疾病中有用的化合物。本发明的化合物，单独或与其他药用活性剂结合使用，可用于治疗或预防神经系统疾病。

  公开号：

  WO2021247893A1
• 作为产物：
  描述：

  2-甲基噻唑-5-甲酸 在 氯甲酸乙酯 、 三乙胺 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.0h， 以25%的产率得到2-甲基噻唑-5-基)甲醇
  参考文献：
  名称：

  [EN] IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS
  [FR] COMPOSÉS IMIDAZO-PYRIDINE À UTILISER EN TANT QU'INHIBITEURS DE PAD

  摘要：

  公式（I）、（II）和（III）的杂环化合物以及它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物在本文中被描述。本文描述的化合物、它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物是PAD4抑制剂，可能在治疗各种疾病中有用，例如类风湿关节炎、血管炎、系统性红斑狼疮、皮肤红斑狼疮、溃疡性结肠炎、癌症、囊性纤维化、哮喘、多发性硬化和牛皮癣。还描述了制备公式（I）、（II）和（III）的化合物、它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物的过程，以及包含公式（I）、公式（II）、公式（III）的化合物或其药学上可接受的盐的药物组合物。

  公开号：

  WO2019077631A1

文献信息

• [EN] PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINES KINASES
  申请人：PHARMASCIENCE INC

  公开号：WO2015077866A1

  公开（公告）日：2015-06-04

  The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated. More particularly, the present invention relates to a compound of Formula I.

  本发明涉及一种新型蛋白激酶抑制剂家族，更具体地说，本发明是针对Tec或Src蛋白激酶家族成员的抑制剂。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗蛋白激酶活性参与的增殖性、炎症性、感染性或自身免疫疾病、紊乱或病症中的用途。更具体地说，本发明涉及一种I式化合物。
• Novel thiazole derivatives
  申请人：Roussel-UCLAF

  公开号：US04032643A1

  公开（公告）日：1977-06-28

  Novel substituted thiazoles of the formula ##STR1## wherein R is alkyl of 1 to 5 carbon atoms and R.sub.1 is selected from the group consisting of --NH.sub.2, -- NH-AlK, ##STR2## PHENYLAMINO AND DIPHENYLAMINO, AlK is alkyl of 1 to 4 carbon atoms and n is an integer from 1 to 6 and their non-toxic, pharmaceutically acceptable acid addition salts having a marked antilipolytic activity and for some of them, a prolonged vasodilatatory activity and an antibradykinetic activity and their preparation.

  公式为##STR1##的新型取代噻唑，其中R是1至5个碳原子的烷基，R.sub.1选自--NH.sub.2，--NH-AlK，##STR2## PHENYLAMINO和DIPHENYLAMINO的群组，AlK是1至4个碳原子的烷基，n是1至6的整数，以及它们的无毒、药学上可接受的酸盐，具有显著的抗脂解活性，对其中一些化合物而言，还具有持久的血管扩张活性和抗缓激肽活性，以及它们的制备。
• 杂芳化合物及其在药物中的应用
  申请人：广东东阳光药业有限公司

  公开号：CN106749268B

  公开（公告）日：2020-10-09

  本发明公开了杂芳化合物及其在药物中的应用，具体地，本发明提供一类杂芳化合物或其立体异构体，几何异构体，互变异构体，消旋体，氮氧化物，水合物，溶剂化物，代谢产物，药学上可接受的盐或前药，以及包含所述化合物的药物组合物；本发明还公开了所述化合物或其药物组合物在制备药物中的用途，及其在治疗自体免疫疾病或增殖性疾病方面的应用。
• Retroviral protease inhibiting piperazine compounds
  申请人：Abbott Laboratories

  公开号：US05455351A1

  公开（公告）日：1995-10-03

  Retroviral protease inhibiting compounds of the formula: ##STR1## are disclosed.

  翻译结果为：公开了具有以下公式的逆转录病毒蛋白酶抑制化合物：##STR1##。
• [EN] 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG<br/>[FR] DÉRIVÉS DE 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE EN TANT QU'INHIBITEURS DE LA PARG
  申请人：CANCER REC TECH LTD

  公开号：WO2016092326A1

  公开（公告）日：2016-06-16

  The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

  本发明涉及作为PARG（Poly ADP-ribose glycohydrolase）酶活性抑制剂的I式化合物，其中R1a、R1b、R1c、R1d、R1e、W、X1、X2、X3、X4、X5、X6、X7、c如本文所定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及其他涉及PARG活性的疾病或症状中的用途。